VVT Medical is proud to share that as of June 2022, our ScleroSafe™ platform for the treatment of Varicose Veins has been certified and approved by the TGA, The Australian department of health’s Therapeutic Goods Administration, to be promoted in Australia and New-Zealand by Getz Healthcare, our distribution partner in South-east Asia.
Varicose Veins are a medical condition that 356 million people are estimated to suffer from worldwide. Also known as Chronic Venous Insufficiencies (CVI), constituting a large and expanding treatment need. The problem impacts up to 40% of women and 17% of men in the United States4. Varicose Veins result from valve disorders, causing blood to accumulate in the lower leg instead of flowing upward to the heart.
Getz Healthcare was established over 110 years ago and is the leading distributor of medical devices & equipment in Asia Pacific, selling in Australia & New-Zealand, Hong-Kong & Macau, Malaysia, Pakistan, Philippines, Taiwan, Thailand and Vietnam.
Getz Healthcare Australia & New-Zealand primarily focuses on: Interventional Radiology, Venous Health, Surgical Equipment, Aesthetics and more.
VVT Medical is an Israeli Medical Device company that develops, manufactures and distributes minimally-invasive, non-thermal, non-tumescent solutions for the treatment of varicose veins for aesthetic and medical needs. The ScleroSafe™ platform is CE approved and VVT Medical is expecting to complete Federal Drug Administration (FDA) 510K submission of the ScleroSafe™ platform by the end of the year.
“Receiving the Australian TGA sets another milestone in the company’s vision, of creating new level of quality for patients suffering from Varicose Veins, says Erez Tetro, VVT Medical’s CEO.
The Australian market demonstrates high demand and need of advanced solutions for this increasing problem. Getz Healthcare is the perfect partner to bring our novel solutions to patients in need.”